What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
His main research concerns Prostate cancer, Cancer research, Cancer, Prostate and Pathology.
Prostate cancer is the subject of his research, which falls under Internal medicine.
The study incorporates disciplines such as Endocrinology and Oncology in addition to Internal medicine.
The concepts of his Cancer research study are interwoven with issues in Bioinformatics, Metastasis, LNCaP, Androgen receptor and Adenocarcinoma.
His work investigates the relationship between Cancer and topics such as Immunology that intersect with problems in Watchful waiting.
His Prostate research includes elements of Immunohistochemistry, Tissue microarray, DNA methylation and Cancer biomarkers.
His most cited work include:
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer (3179 citations)
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
- The polycomb group protein EZH2 is involved in progression of prostate cancer (2107 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Prostate cancer, Cancer research, Cancer, Internal medicine and Pathology.
His research in Prostate cancer tackles topics such as Prostate which are related to areas like Adenocarcinoma.
His studies in Cancer research integrate themes in fields like Carcinogenesis, Gene, Chromoplexy, Metastasis and LNCaP.
Mark A. Rubin has included themes like SPOP, Computational biology, PTEN and Bioinformatics in his Cancer study.
The various areas that Mark A. Rubin examines in his Internal medicine study include Endocrinology and Oncology.
Pathology connects with themes related to Fluorescence in situ hybridization in his study.
He most often published in these fields:
- Prostate cancer (67.65%)
- Cancer research (38.04%)
- Cancer (33.83%)
What were the highlights of his more recent work (between 2016-2021)?
- Prostate cancer (67.65%)
- Cancer research (38.04%)
- Cancer (33.83%)
In recent papers he was focusing on the following fields of study:
Mark A. Rubin focuses on Prostate cancer, Cancer research, Cancer, Internal medicine and Oncology.
His studies deal with areas such as Carcinogenesis, Prostate, SPOP and PTEN as well as Prostate cancer.
His research integrates issues of PI3K/AKT/mTOR pathway and Disease in his study of Prostate.
His Cancer research research includes themes of Lineage, Transcriptome, Organoid, Androgen and Epigenetics.
His research in Cancer intersects with topics in Precision medicine, Clinical trial, Computational biology and Gene.
His Oncology research is multidisciplinary, incorporating perspectives in Biopsy, Cancer biomarkers, Personalized medicine and MEDLINE.
Between 2016 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer (399 citations)
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer (399 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His main research concerns Prostate cancer, Cancer research, Internal medicine, Oncology and Cancer.
His Prostate cancer study combines topics from a wide range of disciplines, such as Transcriptome, Prostate, PTEN and Cancer biomarkers.
His Cancer research study integrates concerns from other disciplines, such as Lineage, Carcinogenesis, Phenotype, Mutation and Transcription factor.
His work in Internal medicine covers topics such as Endocrinology which are related to areas like PI3K/AKT/mTOR pathway.
His Oncology study incorporates themes from Clinical trial and Gene mutation.
The Cancer study combines topics in areas such as Exome sequencing, Immunology, SPOP, Gene and Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
